Amarin Corporation plc Stock Deutsche Boerse AG

Equities

EH3A

US0231112063

Biotechnology & Medical Research

Market Closed - Deutsche Boerse AG 03:11:14 2024-05-31 am EDT 5-day change 1st Jan Change
0.71 EUR -3.40% Intraday chart for Amarin Corporation plc -2.74% -4.70%
Sales 2024 * 202M 186M Sales 2025 * 215M 198M Capitalization 355M 328M
Net income 2024 * -70M -64.55M Net income 2025 * -64M -59.01M EV / Sales 2024 * 1.54 x
Net cash position 2024 * 43.92M 40.5M Net cash position 2025 * 159M 146M EV / Sales 2025 * 0.92 x
P/E ratio 2024 *
-4.91 x
P/E ratio 2025 *
-5.2 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 90.48%
More Fundamentals * Assessed data
Dynamic Chart
European Equities Traded in the US as American Depositary Receipts Open Week Lower in Tuesday Trading MT
Amarin Says Greece Approves Vazkepa for National Reimbursement; Signs Commercialization Agreement With Vianex MT
Amarin Corporation plc Receives National Reimbursement for Vazkepa (Icosapent Ethyl) in Greece by Greek Ministry of Health CI
Amarin Corporation plc Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A CI
European Equities Traded in the US as American Depositary Receipts Kick Off Week Higher MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading; End Week Up Nearly 3% MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Wednesday Trading MT
Bank Stocks Lead European Equities Traded in the US as American Depositary Receipts Higher Tuesday MT
European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Lower in Wednesday Trading MT
Transcript : Amarin Corporation plc, Q1 2024 Earnings Call, May 01, 2024
Earnings Flash (AMRN) AMARIN CORPORATION Posts Q1 Revenue $56.5M MT
Amarin Corporation plc announces an Equity Buyback for $50 million worth of its shares. CI
Amarin Corporation plc Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Amarin Corporation plc authorizes a Buyback Plan. CI
More news
1 day-3.40%
1 week-2.74%
1 month-12.88%
3 months-22.83%
6 months-0.70%
Current year-4.70%
More quotes
1 week
0.71
Extreme 0.705
0.74
1 month
0.71
Extreme 0.705
0.86
Current year
0.71
Extreme 0.705
1.26
1 year
0.57
Extreme 0.565
1.26
3 years
0.57
Extreme 0.565
5.06
5 years
0.57
Extreme 0.565
27.00
10 years
0.57
Extreme 0.565
27.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 52 23-07-17
Director of Finance/CFO 52 22-06-19
Compliance Officer 55 Nov. 14
Members of the board TitleAgeSince
Director/Board Member 45 23-02-27
Chairman 49 23-02-27
Director/Board Member 66 23-02-27
More insiders
Date Price Change
24-05-31 0.71 -3.40%
24-05-30 0.735 -.--%
24-05-29 0.735 +0.68%
24-05-28 0.73 +2.10%
24-05-27 0.715 -2.05%

Delayed Quote Deutsche Boerse AG, May 31, 2024 at 03:11 am EDT

More quotes
Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
3
Last Close Price
0.865 USD
Average target price
1 USD
Spread / Average Target
+15.61%
Consensus